Brentjens RJ - Search Results

1

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.

Adusumilli PS, Zauderer MG, Rivière I, Solomon SB, Rusch VW, O'Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, Pineda J, Perez-Johnston R, Tan KS, Daly B, Araujo Filho JA, Ngai D, McGee E, Vincent A, Diamonte C, Sauter JL, Modi S, Sikder D, Senechal B, Wang X, Travis WD, Gönen M, Rudin CM, Brentjens RJ, Jones DR, Sadelain M. Adusumilli PS, et al. Among authors: brentjens rj. Cancer Discov. 2021 Nov;11(11):2748-2763. doi: 10.1158/2159-8290.CD-21-0407. Epub 2021 Jul 15. Cancer Discov. 2021. PMID: 34266984 Free PMC article. Clinical Trial.

2

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Maher J, et al. Among authors: brentjens rj. Nat Biotechnol. 2002 Jan;20(1):70-5. doi: 10.1038/nbt0102-70. Nat Biotechnol. 2002. PMID: 11753365

3

Targeting tumours with genetically enhanced T lymphocytes.

Sadelain M, Rivière I, Brentjens R. Sadelain M, et al. Nat Rev Cancer. 2003 Jan;3(1):35-45. doi: 10.1038/nrc971. Nat Rev Cancer. 2003. PMID: 12509765 Review.

4

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Rivière I, Sadelain M. Brentjens RJ, et al. Nat Med. 2003 Mar;9(3):279-86. doi: 10.1038/nm827. Epub 2003 Feb 10. Nat Med. 2003. PMID: 12579196

5

Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes.

Rivière I, Sadelain M, Brentjens RJ. Rivière I, et al. Among authors: brentjens rj. Curr Hematol Rep. 2004 Jul;3(4):290-7. Curr Hematol Rep. 2004. PMID: 15217559 Review.

6

Somatic cell engineering and the immunotherapy of leukemias and lymphomas.

Brentjens RJ, Sadelain M. Brentjens RJ, et al. Adv Pharmacol. 2004;51:347-70. doi: 10.1016/S1054-3589(04)51015-3. Adv Pharmacol. 2004. PMID: 15464917 Review. No abstract available.

7

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Rivière I, Larson SM, Koutcher JA, Sadelain M. Gade TP, et al. Cancer Res. 2005 Oct 1;65(19):9080-8. doi: 10.1158/0008-5472.CAN-05-0436. Cancer Res. 2005. PMID: 16204083

8

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintás-Cardama A, Larson SM, Sadelain M. Brentjens RJ, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35. doi: 10.1158/1078-0432.CCR-07-0674. Epub 2007 Sep 12. Clin Cancer Res. 2007. PMID: 17855649

9

T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.

Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. Stephan MT, et al. Among authors: brentjens rj. Nat Med. 2007 Dec;13(12):1440-9. doi: 10.1038/nm1676. Epub 2007 Nov 18. Nat Med. 2007. PMID: 18026115

10

Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application.

Quintás-Cardama A, Yeh RK, Hollyman D, Stefanski J, Taylor C, Nikhamin Y, Imperato G, Sadelain M, Rivière I, Brentjens RJ. Quintás-Cardama A, et al. Among authors: brentjens rj. Hum Gene Ther. 2007 Dec;18(12):1253-60. doi: 10.1089/hum.2007.088. Hum Gene Ther. 2007. PMID: 18052719

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

155 results

Search Page

Filters